Discontinuing GLP-1 weight-loss treatments frequently triggers rapid weight regain, pushing the industry toward post-treatment support and oral formulations.

Novo Nordisk filed a lawsuit against Eli Lilly, claiming the rival firm uses outdated clinical data in its advertisements to misrepresent its obesity drugs.